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Introduction
Acute myeloid leukemia (AML) is a heterogeneous group of
hematologic malignancies characterized by a differentiation
block and unrestricted proliferation of myeloid precursors.
Historically, AML classification was based on phenotypic cri-
teria of the French-America-British (FAB) co-operative group.1
More recently, the World Health Organization (WHO) for-
mulated an up-dated classification based on key genetic
lesions underlying distinct clinico-pathological subgroups.2
With the exception of FAB AML-M3 (acute promyelocytic
leukemia), there is limited overlap between subgroups of the
FAB and WHO classifications. As recent clinical advances in
AML have been driven by better prognostic stratification,3 the
WHO classification has rapidly made its way into routine
clinical practice in view of its prognostic and therapeutic
implications. 
However, advances in AML genomics,4,5 have demonstrat-
ed that even within WHO classes there exists significant het-
erogeneity, which can translate into different clinical out-
comes.6 This is particularly true of patients with normal kary-
otype AML (AML-NK), who could be either over- or under-
treated in the absence of prognostic information. In fact,
AML-NK is driven by a complex interplay of several diverse
leukemogenic mutations that may confer different prognosis
based on their combinatorial patterns of co-occurrence. For
example, the good prognostic value of NPM1- or CEBPA-
mutations6-8 is annulled by the presence of FLT3 internal tan-
dem duplications (FLT3-ITDs)9,10 in the same way as c-KIT
mutations can negate the good prognostic impact of core
binding factor translocations.11 Similarly, other genes or gene
combinations appear to carry prognostic value,5,12 and this is
being assessed in large patient cohorts. Additionally, gene
mutations may serve as therapeutic targets as shown for
example by the clinical efficacy of the tyrosine kinase
inhibitor dasatinib for AML with c-KIT mutations,13,14 and by
therapies targeting FLT3-ITD.15
Next generation sequencing (NGS) technologies introduced
rapid sequencing of entire human genomes.16 AML with nor-
mal karyotype was the first cancer whose genome was fully
sequenced,17 and the spectrum of its genomic alterations has
since been characterized in hundreds of patients.4 Several
technologies are now available that selectively enrich for rel-
evant genes/regions (target enrichment) before NGS is per-
formed. This allows for cheaper multiplexed sequencing of
more cases, and moderates the complexity of downstream
bioinformatics analyses. Such an approach, employing DNA
pulldown with cRNA probes (Sureselect®, Agilent
Technologies) was recently described in AML18 and
myelodysplastic syndromes.19.20 However, this approach suf-
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Prognostic stratification is critical for making therapeutic decisions and maximizing survival of patients with acute
myeloid leukemia. Advances in the genomics of acute myeloid leukemia have identified several recurrent gene
mutations whose prognostic impact is being deciphered. We used HaloPlex target enrichment and Illumina-based
next generation sequencing to study 24 recurrently mutated genes in 42 samples of acute myeloid leukemia with
a normal karyotype. Read depth varied between and within genes for the same sample, but was predictable and
highly consistent across samples. Consequently, we were able to detect copy number changes, such as an inter-
stitial deletion of BCOR, three MLL partial tandem duplications, and a novel KRAS amplification. With regards to
coding mutations, we identified likely oncogenic variants in 41 of 42 samples. NPM1 mutations were the most
frequent, followed by FLT3, DNMT3A and TET2. NPM1 and FLT3 indels were reported with good efficiency. We
also showed that DNMT3A mutations can persist post-chemotherapy and in 2 cases studied at diagnosis and
relapse, we were able to delineate the dynamics of tumor evolution and give insights into order of acquisition of
variants. HaloPlex is a quick and reliable target enrichment method that can aid diagnosis and prognostic stratifi-
cation of acute myeloid leukemia patients. 
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ABSTRACT
fers from the need for laborious library preparation, long
turnaround times and reduced sensitivity for detecting
long insertions such as FLT3-ITDs.18 In this study, we
employed the HaloPlex® (Agilent Technologies) target
enrichment system, which is based on digestion of
genomic DNA to produce fragments tiling target regions,
followed by sequence-specific annealing to custom-made
probes followed by PCR-amplification to produce tagged
amplicons for sequencing. This system uses little input
DNA and promises a more affordable, quick, and efficient
target enrichment that may be more suitable for analysis
in diagnostic laboratories.21 We used HaloPlex to study 24
recurrently mutated genes in 42 AML samples, mostly in
the absence of matched normal DNA. Here we report its
performance in identifying coding and copy number
mutations affecting target genes.
Methods
Samples, DNA target enrichment, sequencing and
alignment
DNA was extracted from bone marrow of 40 AML-NK patients
with more than 80% leukemic infiltrate at diagnosis. All patients
had either karyotyping or multiplex PCR to rule out recurrent
chromosomal translocations (HemaVision®-Screen, DNA
Diagnostic A/S). Tumor samples were compared to an unrelated
normal DNA sample (human placenta) for variant calling. For 2
patients, we collected bone marrow samples at diagnosis and at
molecular relapse, identified by increased NPM1/ABL ratio by RT-
qPCR. For 5 patients, a matched bone marrow sample was also
available post-chemotherapy. Informed consent was obtained
within our ethics-approved study (IRB 07/MRE05/44) and samples
were stored in accordance with the Declaration of Helsinki. The
24 genes studied were selected based on their recurrence rate in
AML and their relevance to pathogenesis and prognosis (Table 1).
The targeting design was generated using an online design tool for
HaloPlex and target enrichment was performed using HaloPlex
standard protocol (v.2.0, November 2011). Briefly, 900 ng of DNA
per sample were aliquoted into 8 digestion reactions, each contain-
ing 2 restriction enzymes. DNA from the 8 reactions was then
pooled, hybridized to HaloPlex probes, and purified using magnet-
ic beads. Fragments were ligated, amplified and barcoded through
19 PCR cycles, and two pools of 12 and 35 samples sequenced on
one lane each of HiSeq2000 (Illumina), 100 bp paired-end proto-
col. 
Before alignment, 5 bp were trimmed from the start of each
read to minimize possible mis-mapping due to restriction site
sequence retention. Paired-end sequencing reads were aligned to
the human genome (NCBI build 37) using BWA.22 Unmapped or
off-target reads were excluded. Apparent PCR duplicates were not
removed as HaloPlex generates fragments of the same start and
end positions that cannot be distinguished from each other before
or after PCR.
On-target performance and copy-number analysis
To determine the coverage of the target region, we used a BED
file encoding the co-ordinates of the coding sequence of each of
the 24 genes and retrieved the number of reads covering each
base-pair position using Bedtools v.2.15.23 We then normalized
coverage in each sample by dividing the read count at each posi-
tion by the total number of on-target mapped bases for that sam-
ple. Coverage data and plots were produced using open-source
software and bespoke R scripts (R v.3.0.3).24 To identify copy num-
ber alterations at individual exons, we compared the average cov-
erage of each exon with that of normal samples. Genes with three
or more exons showing read depths above or below the standard
deviation of normal samples were examined further for amplifica-
tions or deletions. 
Mutation calling algorithms
Substitutions and insertions/deletions were detected using
CaVEMan and Pindel as previously described.19,25,26 Our main aim
was to define driver events and therefore we only reported “likely
oncogenic variants”, defined as variants already reported as somat-
ic in AML literature, or novel variants clustering with known
somatic variant hotspots, or truncating variants in genes implicat-
ed in AML through loss of function mutations. Relevant variants
and copy number events were validated with orthogonal tech-
niques. More details are provided in the Online Supplementary
Appendix.
Results
Patients and sequencing metrics
The target region of 140,811bp did not include UTRs or
introns and was sequenced with a mean coverage of
3,655x [(total output 39.91 gigabases (Gb)] (Figure 1A).
The number of bases mapped on-target per sample was
dependent on the degree of multiplexing and ranged from
0.13 to 1.26Gb (Figure 1A), representing an average of
66.33% of the total output. Unsurprisingly, there was a
correlation between the depth of sequencing and the per-
centage of the target region covered at more than 1000X
HaloPlex in AML diagnosis
haematologica | 2015; 100(2) 215
Table 1. Genes and transcripts used for the targeted enrichment study.
Gene NCBI RefSeq transcripts used (NCBI RefSeq ID)
ASXL1 NM_001164603 NM_015338
BCOR NM_017745 NM_001123385 NM_001123384 NM_001123383
CBL NM_005188
CEBPA NM_004364
CSF1R NM_005211
DNMT3A NM_022552 NM_153759 NM_175629 NM_175630
FLT3 NM_004119
EZH2 NM_152998 NM_004456
IDH1 NM_005896
IDH2 NM_002168
JAK2 NM_004972
KIT NM_001093772 NM_000222
KDM6A NM_021140
KRAS NM_004985 NM_033360
MLL NM_005933
NF1 NM_000267 NM_001042492 NM_001128147
NPM1 NM_002520 NM_001037738 NM_199185
NRAS NM_002524
PTPN11 NM_002834
RUNX1 NM_001001890 NM_001754 NM_001122607
SF3B1 NM_012433 NM_001005526
TET2 NM_001127208 NM_017628
UTY NM_007125 NM_182659 NM_182660
WT1 NM_024426 NM_000378 NM_024424 NM_024425
(P<2.2e-16) (Figure 1A) and at more than 30X, which we
consider the minimum depth for reliable analysis (P=0.04)
(Figure 1A). Coverage of each gene varied between sam-
ples depending on total sequencing output (Figure 1B), as
did coverage of different genes within the same sample
presumably due to factors such as PCR efficiency and GC
content. Nevertheless, our study performed well as all
genes were covered at more than 30X for at least 90% of
their coding regions with the exception of the GC rich and
notoriously hard to target CEBPA19 (Figure 1C). 
Factors affecting local coverage 
Each fragment/read of HaloPlex target enrichment has a
defined start site, unlike target enrichment generated using
shearing, which produces fragments with different start and
end points. We, therefore, asked whether the position of
restriction sites could influence coverage of target regions.
We found significant variability looking at raw coverage
across gene loci within each sample, with read depth fol-
lowing a “square wave” pattern. For example, coverage
across consecutive bases of the CEBPA locus varied by
several fold (Figure 2A), with drops in coverage likely dic-
tated by PCR amplification differences as well as number
and size of amplicons. Some reads of our 100 bp paired-
end sequencing did not reach the middle portion of the
few large amplicons longer than 200bp (Figure 2B) due to
positions of restriction sites used in the genome.
Therefore, we investigated whether amplicon length cor-
related with coverage across the entire target region.
Coverage of amplicons less than 100bp was variable,
whilst amplicons longer than 200 bp showed a percentage
of missed bases that increased proportionally with their
length (Figure 2C). Unsurprisingly, we found that coverage
at each base-pair position strongly correlated with the
number of amplicons covering it (Figure 2D), suggesting
that tiling more amplicons over a region rescued coverage
gaps in long amplicons. This also explains why not all
amplicons longer than 200 bp demonstrate a drop in cov-
erage (Figure 2C), as this phenomenon was mainly limited
to regions covered by single amplicons. Finally, we asked
if coverage was influenced by length of exons rather than
amplicons, and we found that this was not the case (Figure
2E), again suggesting that tiling regions of interest with
multiple amplicons can overcome gaps of coverage within
long amplicons. Our data show therefore that the regional
drops in coverage of HaloPlex target enrichment are pre-
dictable based on amplicon length and tiling, and not
influenced by the size of the region/feature of interest.
These factors should be considered as part of HaloPlex tar-
get enrichment designs.
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Figure 1. (A) Stacked bar chart
showing the total sequence output
in gigabases (Gb, left y-axis) per
sample: gray, bases unmapped; yel-
low, bases mapped off target; blue,
bases mapped on target. Samples
plexed and sequenced in different
HiSeq lanes are segregated by the
dashed vertical line. Lines indicate
the percentage of target covered at
more than 30X (gray) and more
than 1000X (red) – right y-axis. A
Pearson’s test shows the correla-
tion between sequence output and
percentage of target covered at the
above percentages. (B) Bar chart
displaying the absolute coverage of
each gene in the study, calculated
as the mean coverage of that gene
in all samples. Error bars represent
standard deviation. (C) Bar chart
showing, for each gene, the aver-
age percentage of the coding
region covered at more than 30X in
all samples (i.e. the minimum cov-
erage used for variant calling). Error
bars represent standard deviation.
UTY, the Y chromosome homolog of
KDM6A (UTX) was only covered by
males in the study. 
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Detection of copy-number changes
We observed that coverage varied significantly between
different base positions from the same sample; however,
coverage patterns appeared consistent between samples.
In this context, we asked whether HaloPlex target enrich-
ment data could identify copy number aberrations, as is
the case for SureSelect target enrichment.18,19 We normal-
ized coverage of each sample for on-target mapped bases,
and plotted average depth for all genes in our samples
(Figure 3A). All samples showed read depths for X- and Y-
chromosome genes consistent with patient gender, with
females consistently showing an approximately 2-fold
increase in coverage of X-linked genes (BCOR and
KDM6A, also known as UTX) and no coverage of the Y-
linked gene UTY (the Y homolog of KDM6A).
Interestingly, one male sample, PD19747a, showed a
BCOR depth that was lower than other males in the
cohort (black bar in Figure 3A). Coverage of all BCOR
exons was significantly lower compared to the average of
normal male samples (Figure 3B) suggesting this patient
carries a BCOR deletion and this was indeed confirmed by
quantitative PCR (Figure 3C). As sample PD17940a was
previously shown to carry an MLL partial tandem duplica-
tion (PTD),18 we checked coverage of MLL exons between
2 and 10 and found that most showed a higher coverage
than normal samples (Figure 3D) consistent with a dupli-
cation of the region. We found another 2 patients showing
the same pattern (PD17948a and PD17957a, (Figure 3D),
and went on to confirm the presence of MLL-PTDs by
long-range PCR (Online Supplementary Figure S1A). Finally,
one patient showed an amplification involving the KRAS
locus (red bar in Figure 3A), which we confirmed by quan-
titative PCR (Figure 3E) and by CGH/SNP array (Online
Supplementary Figure S1B). 
Given that read depth of gene loci returned a linear esti-
mate of the copy number of the locus, we next looked at
the quantitative value of substitution calls, and to this end
we analyzed 90 of the most polymorphic SNPs within our
target region.27 Of the heterozygous SNP calls, 84.6%
were confined in a narrow allelic fraction window of 50+/-
10% (Online Supplementary Figure S1).
Therefore, despite HaloPlex target enrichment returning
variable coverage of different target regions, this variation
is predictable, consistent across samples, and not signifi-
cantly biased by PCR amplification. Depth of coverage
retained quantitative value at the gene- and base-pair level
and could identify copy number alterations with patho-
genic and prognostic value.
Study controls
We next turned our attention to DNA sequence variants.
First, we demonstrated that our algorithm identified likely
oncogenic somatic variants and not inherited polymor-
phisms without the use of matched normal DNA. We did
this by comparing the 16 variants called by our unmatched
variant detection pipeline to matched post-chemotherapy
DNA in 5 patients for whom this was also available
(Figure 4A). Thirteen of 16 mutations were not present in
the post-chemotherapy sample suggesting these were
somatic mutations. Of 3 patients showing persistence of
one oncogenic variant each, 2 were in complete hemato-
logic remission and one in partial remission with normal
blood counts. Interestingly, the two variants with high
allelic frequency in the post-chemotherapy sample were
DNMT3A R882H substitutions, recently reported to per-
sist in pre-leukemic cells after AML remission.28 The other,
a TET2 nonsense mutation, showed a marked drop in
allelic fraction consistent with incomplete molecular
response. This shows that our pipeline can reliably identi-
fy somatic oncogenic events in unmatched samples, but
underscores the limitation of using post-chemotherapy
samples as matched controls in AML NGS studies.
Next, we confirmed that HaloPlex identifies real vari-
ants by looking at the 25 mutations found in 8 patients
that were previously studied using SureSelect DNA pull-
down.18 These 25 variants included all 23 called by
SureSelect,18 including those present at subclonal level
(Figure 4B), showing a high reliability of HaloPlex calls. An
additional two variants were missed by SureSelect, both
FLT3-ITDs, which are notoriously hard to identify by tar-
HaloPlex in AML diagnosis
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Figure 2. (A) Line graph showing base-by-base average normalized
coverage of the CEBPA gene footprint. The CEBPA coding region is
shown by a thick blue bar and the UTR regions by a thin blue bar. The
horizontal red line highlights positions not covered (0 bp coverage).
Below, the amplicons from HaloPlex design are shown in green. (B)
Boxplot showing the distribution of amplicon size in the design. The
central line is the median, and the box includes values between the
first and third quartile. (C) Plot showing, for each amplicon in the
design (blue dots), the relation between its length (x-axis) and the
percentage of its bases covered at more than 30X. Note that the cov-
erage drops in a fraction of amplicons longer than 200 bp (i.e. the
combined length of the paired-end sequencing protocol), suggesting
that the middle region of such large amplicons was not covered by
either of the 100 bp paired-end reads, and no other amplicons were
overlapping on that region. (D) Boxplot showing, for each base in the
design, the positive correlation between the number of amplicons
covering it (x-axis) and its average coverage in all samples (y-axis).
The central line is the median, and the box includes values between
the first and third quartile. (E) Plot showing that coverage (y-axis) of
individual exons (blue dots) in the design is independent of their
length (x-axis, in log scale). 
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geted enrichment approaches18,29 (E Papaemmanuil,
Wellcome Trust Sanger Institute, personal communication,
2014). Additionally, and notwithstanding the fact that the
allelic burden of indels is hard to assess reliably, the corre-
lation between allelic fractions of variants from the two
enrichment methods was good, indicating that HaloPlex
has similar quantitative properties to SureSelect. 
Caveman is a proprietary algorithm and thus we asked
whether HaloPlex data would allow for reproducible
results with other software. We compared Caveman sub-
stitution calls and allelic frequencies to those generated by
SureCall (v.1.1, Agilent Technologies). SureCall missed 23
of 61 substitutions detected by Caveman, including
known oncogenic ones. All missed variants had an allelic
burden less than 15%, suggesting that SureCall performs
less well in detecting subclonal variants (Figure 4C),
although this may be surmountable by newer versions of
the software. Nevertheless, for variants detected by both
algorithms, the correlation between allelic frequencies
was near perfect (Figure 4C).   
Because NPM1 and FLT3 indels are frequent variants and
key prognostic indicators in AML-NK, we specifically eval-
uated the performance of the open source software Pindel
in detecting these variants as compared to PCR-based
genotyping. NGS and PCR were concordant on the FLT3-
ITD status in 36 of 40 evaluable samples (Figure 4D). In 3
cases, the ITD was found by PCR but not by NGS, and
these were found to be large ITDs that may have not been
amplified or mapped by BWA. In one case, a short ITD was
only found by NGS, and we presume that it represented a
subclonal event that PCR could not detect/discriminate.
Conversely, Pindel only reported NPM1 C-terminal indels
in 7 of 26 cases shown to carry the mutation by PCR.
Looking at NPM1 exon 12, we found a marked coverage
N. Bolli et al.
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Figure 3. (A) For each gene in the study, the normalized average depth of coverage (y-axis) is plotted individually for all patients (x-axis) on a
linear arbitrary scale.  (B) PD17947a (black bar) shows a BCOR deletion involving all exons, whose coverage is lower than the average cover-
age of 3 normal male samples (white bar). The residual signal from all BCOR exons in PD17947a likely reflects that the deletion is subclonal,
although a percentage of normal cells admixed in the tumor sample must also be taken into account. In the particular case of BCOR exon 5
the ratio between WT samples and PD17947a is different compared to neighboring exons, but this must be interpreted with caution. This exon
showed the lowest coverage of all BCOR exons and a high number of homologous regions that could lead to mismapping and make it insen-
sitive to copy number changes. (C) Quantitative PCR on genomic DNA shows lower levels of BCOR exons  1 and 4 in PD17947a (black, solid
and dashed bars, respectively) compared to a control male sample (PD17948a, yellow). (D) PD17940a, PD17948a, and PD17957a (green,
yellow and blue bars, respectively) show an MLL partial tandem duplication as shown by increased coverage of most exons between 1 and 10
compared to the average of 5 normal samples (white bars).  (E) PD17946a (red bar) shows a KRAS amplification confirmed by qPCR on
genomic DNA compared to a control sample in the study.
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drop of position chr 5:170837554, i.e. few bp away from
the insertion site of most NPM1 indels. The reason for this
was that all but one amplicons covering the region were
more than 200bp long, and thus their midpoints were
beyond the reach of either 100bp paired-end read (Figure
4E, bottom panel, arrowhead). This design pitfall also
caused NPM1 indels to be close to the end of the reads, and
thus discarded by Pindel and under-reported. Since only
one amplicon covered the mutation in a position amenable
to sequencing (Figure 4E, asterisk), NPM1 variants were
only called in samples where this amplicon was sequenced
with enough coverage (P=0.01). Nevertheless, NPM1
indels from all amplicons were mapped by BWA, and visu-
al inspection of the reads did allow their identification in all
mutated cases (Figure 4F). To confirm that a short read
length relative to the size of the amplicons covering the
mutations was the reason for the poor detection of NPM1
indels, we re-sequenced HaloPlex libraries for 33 samples
using MiSeq (Illumina) with a 150bp paired-end protocol.
As expected, coverage of the NPM1 indel region was much
higher (Figure 4E, green line), and all indels were called by
Pindel (Figure 4G) with 100% sensitivity and specificity
(Figure 4H). The presence of NPM1 mutations was further
validated by capillary sequencing in all but one sample for
which we did not have additional DNA (Online
Supplementary Table S2). 
HaloPlex in AML diagnosis
haematologica | 2015; 100(2) 219
No ITD - ITD
Mutation burden at diagnosis and remission
Detection of NPM1 indels
NPM1 locus
r=0.82 r=0.98
150 bp - PE
150 bp - PE  
A
B C
E
F
G
H
D
Figure 4. (A) For 5 patients in the study for whom a post-chemotherapy sample was available, the somatic status of 16 variants was checked.
The y-axis represents the raw allelic fraction of the variant, and the x-axis represents individual variants, clustered by patient, in the tumor
(blue bar) and remission (yellow) sample. Note that DNMT3A R882H persists at a similar allelic fraction in post-chemotherapy samples, inde-
pendent of the remission status of the patient. Also, the persistence of a low-level TET2 p.L1119* nonsense mutation suggests that patient
had a partial molecular response to treatment. (B) For 25 variants, validation data was available from a previous study performed with
SureSelect target enrichment. The plot shows the allelic fraction of variants in the HaloPlex study (x-axis) and that of the SureSelect study (y-
axis). Variants are represented as solid circles (substitutions) or open triangles (indels), and are blue if shared between the two studies and
yellow if only reported by the HaloPlex study. The plot shows good correlation of allelic fraction between the two studies. (C) For the 61 sub-
stitutions in the study, two different algorithms were compared (Caveman and SureCall). Shared variants are in blue, variants missed by
SureCall are in yellow. For the shared variants, the correlation between allelic fractions is near perfect. (D) For 40 samples in the study (x-axis),
FLT3-ITDs are plotted by length (y-axis, value=0 if no ITD present). Variants confirmed by both Pindel and PCR are blue circles, those only found
by PCR are yellow upwards triangles, and those only found by NGS are yellow downwards triangles. (E) (Top) Black line shows base-by-base
average normalized coverage of the NPM1 gene locus. The NPM1 coding region is shown by a thick blue bar and the UTR regions by a thin
blue bar. Predicted amplicons from HaloPlex design are shown in green. (Bottom) Zoomed-in view of NPM1 exon 12. Coverage by 100 bp reads
is shown as a black line and leaves a 1-bp gap close to the NPM1c+ insertion site. The amplicon closer to NPM1c+ mutations and allowing
their identification is highlighted by an asterisk, while the amplicons where such mutations were missed are marked by an arrowhead. When
150 bp reads are employed (green line), coverage of the middle region increases.  (F) Aligned reads from a 100 bp sample where the mutation
was missed because of short read length leaving a gap in coverage (arrow). Yellow: reverse reads. Blue: forward reads. The presence of the
indel must be deducted by the BWA calls (red boxes, arrowheads). (G) Aligned reads from a 150 bp sample where the mutation was identified.
Yellow: reverse reads. Blue: forward reads. The insertion is identified by Pindel as green boxes (arrow). (H) Stacked bar chart showing the
increase in sensitivity of Pindel for detection of NPM1 indels with a 150 bp protocol. 
Overall, 115 of 119 variants identified by HaloPlex were
studied by PCR and/or MiSeq. Of the 103 that passed
quality control, 96 were confirmed. Importantly, we could
validate both clonal and subclonal variants indicating that
HaloPlex can enrich target DNA allowing identification of
variants across a range of allelic frequencies. Of the
remaining 7 variants, 4 were false positives and 3 were
sublclonal indels below the detection threshold of stan-
dard PCR  (Online Supplementary Table S2).
Gene mutations 
We reported 119 variants in 20 genes in 41 out of 42
samples, with a median of 3 variants per sample (Figure
5A and Online Supplementary Table S2). The most frequent-
ly mutated gene was NPM1 (62%), followed by FLT3
(50%), DNMT3A and TET2 (33% and 29%, respectively).
As previously described, there was a positive correlation
between NPM1 mutations and FLT3 (Fisher’s exact;
P=0.008). We also observed a tendency towards correla-
tion between NPM1 and DNMT3A, and towards mutual
exclusivity between TET2 and IDH1/2 mutations. Two or
more FLT3-ITD alleles were identified in 3 of 14 samples.
Allelic frequency could not be reliably estimated in these
indels making it impossible to determine if they occurred
in the same cells (compound heterozygosity), or in differ-
ent subclones of the tumor (convergent evolution).
Similarly, two TET2 mutated alleles were found in 2 of 10
patients, reflecting a heterogeneous and evolving muta-
tional pattern. Lastly, we annotated a p.S1018Y missense
variant in UTY, a paralog of KDM6A not implicated in
AML before. The variant was previously reported as
somatic in a gastrointestinal cancer invoking a possible
pathogenic role in AML.
While allelic frequency can be used to assess the sub-
clonal structure of tumors,25 most of our variants were rep-
resented by indels and this precluded such analysis.
Nevertheless, in 2 patients for whom paired diagnosis-
relapse samples were available, we showed loss of a sub-
clonal TET2 mutation in PD17932, and loss of a biallelic
FLT3-ITD and a subclonal FLT3 N676K substitution in
PD17936 at molecular relapse (Figure 5B). This confirms
that the subclonal structure of AML can develop through
continuous acquisition of subclones with new driver
mutations and loss of others, in a pattern consistent with
branching evolution and differential sensitivity to
chemotherapy as has been shown by others.28,30 
Discussion
Dramatic advances in defining the somatic genome of
AML4 have defined the major mutational drivers of this
disease.31 As a result, the field is ready for targeted follow-
up studies aimed at better characterizing the prevalence,
prognostic value and pathogenic role of these genetic
lesions in large cohorts of patients. Indeed, information on
mutated genes is making its way into new prognostic
models,5 especially in cases without recurrent karyotype
rearrangements.12 In this paper, we describe a rapid, robust
and high-throughput approach for the characterization of
gene mutations and copy number changes in AML sam-
ples using HaloPlex target enrichment followed by NGS
and standard bioinformatic analysis. We showed that
amplicon tiling and read length relative to amplicon length
are the two most important parameters affecting coverage
of target regions. In HaloPlex, the position of restriction
sites limits the extent to which sequencing start sites and
amplicon lengths can be customized in the target enrich-
ment design. Therefore, depending on tiling and amplicon
length, adjacent genomic regions can show variable cover-
age. While the automated HaloPlex design tool works well
in general, if mutational hotspots are anticipated it is
advisable that these positions are checked manually to
ensure they will be adequately covered. We showed that
variability of coverage of HaloPlex data is reproducible
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Figure 5. (A) Highlights relevant genetic alterations and recurrently mutated genes in the
study. Samples are represented in columns. Recurrently mutated genes are color-coded for
missense (blue), nonsense (red), splice-site (green) the substitutions, and indels (yellow). In
the case of multiple mutations of the same class in a gene in a patient, a black contour is
drawn. If two mutations of a different class are present, the box is filled by two triangles. For
each gene, the number of patients harboring at least one non-silent mutation is provided in
the “TOTAL” column. (B) For 2 patients for whom diagnosis (D) and relapse (R) samples where
available, the mutational spectrum is provided to show evolution of the cancer over time.
A
B
and consistent across samples. Normalized coverage of
each gene locus correlated with its copy number status,
relative to the other samples in the cohort. This enabled us
to identify small copy number changes without the need
for matched normal DNA, as exemplified by the identifi-
cation of 3 cases of MLL-PTDs. Furthermore, we report
the novel finding that KRAS can be amplified and BCOR
deleted in AML, reflecting the power of NGS techniques
to interrogate tumor genomes in a high-throughput fash-
ion. Clinical follow up was not available for our patients,
and future studies will define the recurrence rate and prog-
nostic role of these events in AML. Compared to genome-
wide CGH arrays, we could only infer copy number of
regions targeted in our design. Nevertheless, in the future,
this property could be harnessed for the capture and study
of a large number of polymorphic SNPs evenly spaced
across the genome to allow the identification of whole-
genome copy-number and loss-of-heterozygosity
changes. 
Our study had a positive predictive value of 96% for the
identification of recurrent mutations in AML. Its ability to
report indels, a frequent event in AML, was especially
good. Large genomic insertions such as MLL-PTDs were
identified by copy-number profile of individual exons.
While NPM1 indels were initially under-reported by 100
bp reads because of a design flaw, employing longer reads
allowed us to achieve 100% accuracy. We also found good
efficiency for FLT3-ITDs, as we identified 14 of 17 ITD
samples. This was facilitated by targeting both FLT3 exons
and introns around the breakpoints, although the allelic
fraction of such events was lower than expected for driver
mutations. Therefore, we could only capture and/or map
a fraction of the mutated DNA molecules, and our detec-
tion sensitivity could have been lower had we not
sequenced so deeply. Capture, mapping and quantifica-
tion of FLT3-ITD alleles is a major challenge that will likely
require bespoke targeting and bioinformatic approaches,
especially for longer ITDs that were missed in our
study.29,32 On the other hand, we suggest that deep
sequencing can provide increased sensitivity for short and
subclonal ITDs that may be easily missed by conventional
PCR, leading to incorrect prognostic characterization of
the patient. Indeed, in our study we identified 3 subclonal
NPM1 and FLT3 indels that could not be confirmed by
PCR followed by agarose gel electrophoresis or capillary
sequencing. We believe these were true positive results,
and the fact that other subclonal variants were validated in
our study suggests their veracity. Subclonality in AML is
increasingly recognized as a biological event with clinical
implications.28,30,33 HaloPlex target enrichment led to the
identification and validation of a number of subclonal vari-
ants, and loss/gain of variants at AML relapse. This has the
potential to inform on the order of acquisition of such
variants during pre-clinical stages of leukemia develop-
ment and suggests that future, larger studies may be able
to inform which variants are associated with better
response to chemotherapy and which ones are most likely
to confer chemoresistance. For example, our finding that
TET2mutations can be lost at relapse confirms that muta-
tions in this gene can be late34 as well as early35 events in
AML. Also, further studies will be required to assess the
prognostic value of DNMT3A R882H persistence at mor-
phological remission, and whether this variant should be
used for assessment of minimal residual disease. 
We anticipate that NGS technologies will soon be used
for a combined gene sequencing and copy number analy-
sis of tumors, thus providing a one-stop diagnostic plat-
form that has the potential to enhance current analysis
relying on the integration of karyotype, FISH, PCR and
RT-PCR data. Future studies with large numbers of
patients and longitudinal follow up will establish the diag-
nostic and prognostic value of recurrent abnormalities,
and in our paper we show that HaloPlex target enrichment
can provide a solid platform for this exercise.
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